Arrayjet’s ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies

Rhea-AI Summary

Arrayjet partners with Immunome, Inc. (IMNM) to provide its ArrayPlex™ discovery platform for high-throughput screening of targeted cancer therapies. Arrayjet's inkjet technology enables rapid multi-layered assays with two-million data points per cycle, enhancing the discovery of unique binding interactions.

Insights

Biotechnology Analyst

The adoption of Arrayjet's ArrayPlex discovery platform by Immunome, a biotechnology firm focused on cancer therapies, is indicative of the platform's potential to streamline the discovery process. ArrayPlex utilizes inkjet bioprinting technology to create multi-layered assays, which can be pivotal in identifying novel interactions between two libraries—such as antibody and lysate libraries—without prior knowledge of the ligands or targets involved. This is particularly significant for the biotech industry, as it could accelerate the discovery of new cancer treatments by generating a vast number of data points in a single screening cycle, which is a leap forward from traditional methods like ELISA.

For Immunome, internalizing this technology signifies a strategic move to enhance their research capabilities and potentially reduce reliance on external CRO/CMO services. This could result in cost savings and faster development times for their cancer therapy pipeline. For Arrayjet, the deal reinforces the commercial viability of their technology and could lead to increased market penetration. The biotech sector often values such technological advancements, which can be reflected in the stock performance of the companies involved.

Market Research Analyst

From a market perspective, the collaboration between Arrayjet and Immunome may signal a trend where biotech companies are increasingly seeking to bring advanced technologies in-house. The decision by Immunome to purchase an ArrayPlex instrument demonstrates a confidence in the platform's ability to deliver meaningful results in the competitive field of cancer therapeutic discovery. For investors, such partnerships can be interpreted as a company's commitment to innovation and could be a positive indicator of its future growth potential.

Moreover, Arrayjet's CRO/CMO services, coupled with the option for customers to purchase instruments for in-house use, presents a dual revenue stream that can be attractive from an investment standpoint. It showcases the company's flexibility in meeting customer needs and adapting to different business models. The impact of such deals on the stock market can vary, but typically, announcements of technological adoption by reputable firms tend to be viewed favorably by investors, potentially leading to an uptick in stock valuation for both companies involved.

Financial Analyst

Analyzing the financial implications of this deal, the initial outlay for the ArrayPlex system by Immunome is an investment that could lead to long-term financial benefits through enhanced R&D capabilities. The ability to conduct high-throughput screening in-house can reduce costs associated with outsourcing and potentially accelerate the time-to-market for new therapies. This can have a positive effect on Immunome's financial health and its attractiveness to investors.

For Arrayjet, this deal not only generates direct revenue from the sale but also opens the door for future sales of consumables and maintenance services associated with the ArrayPlex system. This creates a recurring revenue model that can enhance the company's financial stability. Additionally, successful implementation and results from Immunome can serve as a case study to promote the ArrayPlex system to other potential clients, potentially increasing Arrayjet's market share and revenue in the long run.

• Arrayjet’s patented spot-on-spot microarray screening technology is available for customers to adopt in-house and via Arrayjet’s CRO/CMO services
• Immunome signs deal to use Arrayjet platform in its in-house screening operations

EDINBURGH, Scotland--(BUSINESS WIRE)-- Arrayjet, a leading provider of inkjet liquid-handling solutions, today announced that its ArrayPlex™ discovery platform has been selected by Immunome, Inc. (NASDAQ: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, to expand its in-house high-throughput screening tools. The proprietary multi-layer microarray platform is also available to Arrayjet’s screening customers through its CRO/CMO services or by the customer purchasing an instrument and performing screening in-house.

ArrayPlex was created by Arrayjet to meet the unique assay requirements of its customers for high-throughput screening services and tools. During Arrayjet’s successful seven-year partnership with Immunome, Arrayjet performed screening services using the ArrayPlex platform, and the platform underwent further optimisation, most recently to integrate internal assay controls and enhanced data normalisation. Arrayjet is pleased that Immunome has now chosen to purchase an instrument and internalise the ArrayPlex assay as an in-house, high-throughput screening resource in its efforts to discover targeted cancer therapies.

Harnessing Arrayjet’s unique inkjet technology for bioprinting, ArrayPlex is a patented spot-on-spot microarray platform that enables the rapid creation of multi-layered assays. This approach allows two libraries to be screened against each other for unique binding interactions, generating hits without prior knowledge of either ligand or target at very high-throughput – typically providing two-million data points per one 10-day cycle. In addition to screening between antibody and lysate libraries, the platform is also compatible with a broad spectrum of other sample types (e.g. small molecule libraries, protein panels, nucleic acid libraries), detecting hits at an equal or higher sensitivity compared to ELISA.

Dr Iain McWilliam, Chief Executive Officer of Arrayjet, commented: “ArrayPlex is a major success story for Arrayjet; a culmination of years of hard work.” He added: “Over the years, we have screened hundreds of thousands of antibodies against hundreds of cancer tissue lysates all the while honing the assay. As a team, we are proud to see ArrayPlex incorporated into Immunome’s powerful in-house operations as one of its tools for advancing cancer therapeutic discovery, and we are excited about the platform also being available to our wider customer base.”

For more information on Arrayjet’s ArrayPlex microarray platform: https://arrayjet.com/arrayplex-multilayered-microarrays

View source version on businesswire.com: https://www.businesswire.com/news/home/20240318967253/en/

Dr Maria Spyrou

Zyme Communications

Email: maria.spyrou@zymecommunications.com

Tel: +44 (0) 7707049640

Source: Arrayjet

FAQ

What is the name of the company Arrayjet partnered with for high-throughput screening of targeted cancer therapies?

Arrayjet partnered with Immunome, Inc. (IMNM) for high-throughput screening of targeted cancer therapies.

What is the name of the discovery platform provided by Arrayjet for this partnership?

Arrayjet provided its ArrayPlex™ discovery platform for high-throughput screening of targeted cancer therapies.

How many data points does Arrayjet's ArrayPlex platform typically provide per one 10-day cycle?

Arrayjet's ArrayPlex platform typically provides two-million data points per one 10-day cycle.

What type of technology does ArrayPlex use for bioprinting in high-throughput screening?

ArrayPlex uses Arrayjet's unique inkjet technology for bioprinting in high-throughput screening.

What sample types is the ArrayPlex platform compatible with for screening?

The ArrayPlex platform is compatible with a broad spectrum of sample types, including small molecule libraries, protein panels, and nucleic acid libraries.